NewLink slides on HyperAcute Pancreas update

NewLink Genetics Corp. (NASDAQ:NLNK) fell $6.11 (16%) to $31.60 on Friday after an independent DSMC said the Phase III IMPRESS trial evaluating NewLink's HyperAcute Pancreas algenpantucel-L for surgically resected pancreatic cancer did not meet the predefined statistical threshold to stop the trial early. The DSMC recommended continuing the trial based on a planned interim analysis following 222 patient deaths; a second interim analysis is scheduled when there are 333 patient deaths. NewLink has an SPA from FDA for the open-label trial, which is evaluating chemotherapy with and without HyperAcute Pancreas. The primary endpoint is overall survival (OS). ...